National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) sits in the top decile of US sponsors by registered trial count (#253 of 15,742 sponsors by registered trial count).
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): 93 sponsored US clinical trials, 12 recruiting.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) sponsors 93 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 71 completed. 4 of these trials are in Phase 3-4 (later-stage) and 45 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arthritis, with 4 trials.
Top-decile sponsor footprint
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ranks in the top decile of sponsors by registered trial count (#253 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
71 of 80 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
93 total, page 1 of 2
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422
Natural History of Inflammatory Muscle Diseases
NCT05738824
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
NCT05567198
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
NCT03510442
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease
NCT02504879
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
NCT02471352
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
NCT02257866
Effects of Treatments on Atopic Dermatitis
NCT01631617
Natural History and Development of Spondyloarthritis
NCT01422694
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
NCT00059748
Studies of the Natural History of Rheumatic Diseases
NCT00024479
Study of Systemic Lupus Erythematosus
NCT00001372
Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
NCT02281747
Natural History and Pathogenesis of Alopecia in Children and Adults
NCT05502796
Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases
NCT04690816
Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus
NCT04233164
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
NCT03395340
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
NCT02535689
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
NCT02338999
Omalizumab for Lupus
NCT01716312
Anakinra for Inflammatory Pustular Skin Diseases
NCT01794117
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
NCT01801449
Anakinra for Behcet s Disease
NCT01441076
Genetic Basis of Primary Immunodeficiencies
NCT00001788
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
NCT01360099
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
NCT00556439
Insulin Resistance and Atherosclerosis in Women With Lupus
NCT00544102
A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
NCT00353158
Progression of Spinal Fusion in Ankylosing Spondylitis
NCT00085995
Interleukin-1 Trap to Treat Autoinflammatory Diseases
NCT00094900
Osteoarthritis Initiative (OAI): A Knee Health Study
NCT00080171
Electromagnetic Treatment For Bone Loss After Forearm Fracture
NCT00067834
Protective Brace to Prevent Hand and Arm Injuries
NCT00074893
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
NCT00069329
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
NCT00056719
Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine
NCT00062465
Genetic Determinants of Ankylosing Spondylitis Severity
NCT00056849
Clinically Important Changes in Rheumatoid Arthritis
NCT00056602
Gabapentin in Fibromyalgia Trial (GIFT)
NCT00057278
Image Guided System for Orthopaedic Surgery
NCT00022802
Monoclonal Antibody Treatment for Systemic Lupus Erythematosus
NCT00046774
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
NCT00042523
Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women
NCT00043719
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
NCT00040651
Management of Compartment Syndrome With Ultrafiltration
NCT00022815
Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis
NCT00033891
The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept
NCT00034060
Blood Component Collection From Patients With Rheumatic or Kidney Disease and Healthy Volunteers
NCT00031174
Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity
NCT00029926
Infliximab to Treat Children With Juvenile Rheumatoid Arthritis
NCT00029042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 27 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) pipeline
12 recruiting of 93 indexed (13% open); 71 completed (76%).
Phase mix: 4 late (III/IV) vs 45 early (I/II) (early-phase heavy).
Top condition: Arthritis (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): open-pipeline peers nationwide
Peers matched on 93 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 93 trials (± recruiting share)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 93 trials · 17% recruiting
- Roxane Laboratories · 93 trials · 0% recruiting
- Colorado State University · 94 trials · 21% recruiting
- Endeavor Health · 94 trials · 20% recruiting
Sponsors near 13% open enrollment (± trial volume)
- McMaster University · 13% recruiting · 31 trials
- Temple University · 13% recruiting · 163 trials
- University of Pittsburgh · 13% recruiting · 1,238 trials
- Intermountain Health Care · 13% recruiting · 85 trials
Related
What to do with this National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) page
93 registered trials is a research-attention snapshot, not an endorsement of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) or any single study.
- 12 of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Arthritis is the condition National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arthritis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) pipeline card: 93 registered trials from official public datasets.Report a data error.